[{"address1": "11682 El Camino Real", "address2": "Suite 120", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 771 9307", "website": "https://ars-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.", "fullTimeEmployees": 24, "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 7.73, "open": 7.85, "dayLow": 7.69, "dayHigh": 8.19, "regularMarketPreviousClose": 7.73, "regularMarketOpen": 7.85, "regularMarketDayLow": 7.69, "regularMarketDayHigh": 8.19, "forwardPE": -13.17742, "volume": 809488, "regularMarketVolume": 809488, "averageVolume": 537677, "averageVolume10days": 489000, "averageDailyVolume10Day": 489000, "bid": 8.15, "ask": 8.2, "bidSize": 100, "askSize": 100, "marketCap": 791634560, "fiftyTwoWeekLow": 2.55, "fiftyTwoWeekHigh": 11.27, "priceToSalesTrailing12Months": 79163.45, "fiftyDayAverage": 8.8494, "twoHundredDayAverage": 6.756, "currency": "USD", "enterpriseValue": 568219264, "floatShares": 42928474, "sharesOutstanding": 96895296, "sharesShort": 6869975, "sharesShortPriorMonth": 6087282, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0709, "heldPercentInsiders": 0.23469, "heldPercentInstitutions": 0.62234, "shortRatio": 14.78, "shortPercentOfFloat": 0.1337, "impliedSharesOutstanding": 96895296, "bookValue": 2.318, "priceToBook": 3.52459, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -49696000, "trailingEps": -0.52, "forwardEps": -0.62, "enterpriseToRevenue": 56821.926, "enterpriseToEbitda": -9.174, "52WeekChange": 0.29067934, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SPRY", "underlyingSymbol": "SPRY", "shortName": "ARS Pharmaceuticals, Inc.", "longName": "ARS Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1607092200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d8a743bf-b873-3187-ac17-afe99130ffb3", "messageBoardId": "finmb_585213447", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.17, "targetHighPrice": 19.0, "targetLowPrice": 19.0, "targetMeanPrice": 19.0, "targetMedianPrice": 19.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 223632000, "totalCashPerShare": 2.308, "ebitda": -61935000, "totalDebt": 217000, "quickRatio": 60.363, "currentRatio": 60.899, "totalRevenue": 10000, "debtToEquity": 0.097, "returnOnAssets": -0.15538, "returnOnEquity": -0.20492001, "freeCashflow": -34366376, "operatingCashflow": -53547000, "operatingMargins": -6199.9, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]